Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PNOC044: Liothyronine (L-T3) in Combination With Bevacizumab, Irinotecan and Temozolomide (BIT) for Progressive or Relapsed Medulloblastoma (Cohort 1) or as Monotherapy for Medulloblastoma With Minimal Residual Disease (Cohort 2)

NCT07346157 is registered in ClinicalTrials.gov with Sabine Mueller, MD, PhD as lead sponsor.

NCT NCT07346157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07346157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PNOC044: Liothyronine (L-T3) in Combination With Bevacizumab, Irinotecan and Temozolomide (BIT) for Progressive or Relapsed Medulloblastoma (Cohort 1) or as Monotherapy for Medulloblastoma With Minimal Residual Disease (Cohort 2)
Lead sponsor
Sabine Mueller, MD, PhD
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 21, 2026
Completion date
March 31, 2031
Enrollment
69 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

medulloblastoma, medulloblastoma recurrent, medulloblastoma, childhood